Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
A state-by-state and federal review of psychedelics-related bills introduced or advanced in February 2026, including pilot programs, trigger laws, and research programs.
In the third video of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look at some broader open questions and potential futures in the psychedelics field via a narrated presentation.
In this conversation with Psychedelic Alpha’s Josh Hardman, Dr. Terence Ching discusses his journey into the field and current work leading Yale’s psilocybin trials for OCD. He reflects on study design considerations, potential mechanisms of action, and some of the subjective phenomena observed during psilocybin sessions in those studies. Dr. Ching also explores what experience and data suggest about integrating psychedelics with evidence-based treatments like CBT and ACT.
Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out • RAND Survey: Americans Divided on Psilocybin Legalisation • Helus’ Phase 2a Study of Intravenous DMT in MDD Published in Nature Medicine • Transcend’s Phase 2 Study of Methylone in PTSD Publishes in JAMA Psychiatry • Large German Psilocybin Trial Misses Primary Endpoint • Latest Data from Aus Reports 188 Patients Treated • FDA’s ‘One Pivotal Trial’ Default • and more…
Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression.
We present the psychedelic drug development pipeline in two ‘bullseye chart’ formats, as of Q1 2026.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into psychedelic dosing and ceremony through interviews, research reviews, and practitioner perspectives.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
Archived versions of our Psychedelic News Feed.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing February 16, 2026.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 26, 2026.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 19, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 12, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 05, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 15, 2025.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).
Insights and interviews delivered to your inbox. No spam, just valuable information.
